EHA 2016 satellite symposium

Optimizing treatment for patients with CP-CML and Ph+ ALL

The 2016 European Hematology Association (EHA) Annual Congress took place during 912 of June, at the Bella Center in Copenhagen, Denmark.  During the congress, a panel of experts came together for an Incyte-sponsored satellite symposium entitled ‘Optimizing Treatment for Patients with CP-CML and Ph+ ALL’.  Chaired by Hagop M. Kantarjian, MD from the University of Texas MD Anderson Cancer Center, Houston, TX, the symposium covered many topics, including discussions on improving patient monitoring and care, the latest tyrosine kinase inhibitor (TKI) trial data, methods of disease mutation analysis, and the role of allogeneic stem cells.

All educational videos in this feature were sponsored by Incyte and were recorded at EHA 2016.

Presentations
Welcome and introduction
Chair: Hagop M. Kantarjian, MD
9 June, 2016

Hagop M. Kantarjian, MD from the University of Texas MD Anderson Cancer Center, Houston, TX makes the opening remarks for the satellite symposium on 'Optimizing Treatment for Patients with CP-CML and Ph+ ALL' at the 2016 European Hematology Association (EHA) Annual Congress, Copenhagen, Denmark.

CML - chronic disease vs. risk of leukemia - how can optimal monitoring improve patient care?
Speaker: Martin C. Müller, MD
9 June, 2016

Martin C. Müller, MD from the University Hospital Mannheim, University of Heidelberg, Mannheim, Germany presents on chronic myeloid leukemia (CML) at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark. Dr Müller discusses chronic disease versus risk of leukemia and how optimal monitoring can improve patient care.

PACE 4-year update
Speaker: Jane Apperley, MBChB, MD, FRCP, FRCPath
9 June, 2016

Jane Apperley, MBChB, MD, FRCP, FRCPath from Imperial College, London, UK presents on the 4-year results from the Phase II PACE trial on ponatinib in heavily pre-treated chronic myeloid leukemia (CML) patients (NCT01207440) at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark. Prof. Apperley provides insight into the PACE trial, focusing on the outcomes of patients with chronic-phase CML.

Question & Answer Session 1
Chair: Hagop M. Kantarjian, MD
9 June, 2016

In the first question and answer session of the satellite symposium on 'Optimizing Treatment for Patients with CP-CML and Ph+ ALL', the audience is invited to ask Dr Müller and Prof. Apperley questions regarding their presentations on chronic myeloid leukemia (CML) at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark.

Where is today's medical need for patients with Ph+ ALL?
Speaker: Philippe Rousselot, MD, PhD
9 June, 2016

Philippe Rousselot, MD, PhD from the Versailles Hospital and University, Versailles, France discusses the current medical need for patients with Ph+ acute lymphoblastic leukemia (ALL) at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark. Dr Rousselot’s presentation covers two aspects of ALL; minimal residual disease (MRD) and mutation analysis.

Is stem cell transplantation still an option for patients with Ph+ ALL achieving CMR?
Speaker: Hagop M. Kantarjian, MD
9 June, 2016

Hagop Kantarjian, MD from the University of Texas MD Anderson Cancer Center, Houston, TX questions whether it is possible to cure Ph+ acute lymphoblastic leukemia (ALL) without an allogeneic stem cell transplant at the 2016 European Hematology Association (EHA) Annual Congress, Copenhagen, Denmark. Dr Kantarjian presents data on tyrosine kinase inhibitor therapy for Ph+ acute lymphoblastic leukemia, arguing that it is possible to treat patients without allogeneic stem cell transplant.

Question & Answer Session 2
Chair: Hagop M. Kantarjian, MD
9 June, 2016

In the second question and answer session of the satellite symposium on 'Optimizing Treatment for Patients with CP-CML and Ph+ ALL', the audience is inviteded to ask Dr Rousselot and Dr Kantarjian questions regarding their presentations on Ph+ acute lymphoblastic leukemia (ALL) at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark.

What is the role of next-generation sequencing in the diagnosis and monitoring of CML and Ph+ ALL?
Speaker: Hugues de Lavallade, MD, PhD
9 June, 2016

Hughes de Lavallade, MD, PhD from the King's College Hospital NHS Foundation Trust, London, UK discusses the role of next-generation sequencing (NGS) in the diagnosis and monitoring of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) whilst presenting at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark. Dr de Lavallade presents the idea that early detection of mutated clones could be used to help determine the best tyrosine kinase inhibitor therapies for patients.

Question & Answer Session 3
Chair: Hagop M. Kantarjian, MD
9 June, 2016

In the third and final question and answer session of the satellite symposium on 'Optimizing Treatment for Patients with CP-CML and Ph+ ALL', the audience is invited to ask Dr de Lavallade questions regarding his presentation on the role of next-generation sequencing in the diagnosis and monitoring of CML and Ph+ ALL at the 2016 European Hematology Association (EHA) Annual Congress in Copenhagen, Denmark.

Panel Discussion & Closing Remarks
Chair: Hagop M. Kantarjian, MD
9 June, 2016

Hagop M. Kantarjian, MD from the University of Texas MD Anderson Cancer Center, Houston, TX
chairs the panel discussion and makes the closing remarks for the satellite symposium on 'Optimizing Treatment for Patients with CP-CML and Ph+ ALL' at the 2016 European Hematology Association (EHA) Annual Congress, Copenhagen, Denmark.